Cantargia Announces IL-17 as Second Target for Bispecific CAN14 Antibody
LUND, SE / ACCESS Newswire / November 9, 2026 / Cantargia AB (publ) (STO:CANTA), a clinical-stage biotechnology company focused on antibody-based therapeutics targeting IL1RAP, today announced IL-17 as the second target for the bispecific antibody …